JP2012508164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508164A5 JP2012508164A5 JP2011533633A JP2011533633A JP2012508164A5 JP 2012508164 A5 JP2012508164 A5 JP 2012508164A5 JP 2011533633 A JP2011533633 A JP 2011533633A JP 2011533633 A JP2011533633 A JP 2011533633A JP 2012508164 A5 JP2012508164 A5 JP 2012508164A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody construct
- single chain
- acute lymphoblastic
- bispecific single
- cd19xcd3 bispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 8
- 208000007660 Residual Neoplasm Diseases 0.000 claims 7
- 230000008707 rearrangement Effects 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 4
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 230000005945 translocation Effects 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims 2
- 238000010222 PCR analysis Methods 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11232308P | 2008-11-07 | 2008-11-07 | |
| US61/112,323 | 2008-11-07 | ||
| US18329109P | 2009-06-02 | 2009-06-02 | |
| US61/183,291 | 2009-06-02 | ||
| PCT/EP2009/007970 WO2010052014A1 (en) | 2008-11-07 | 2009-11-06 | Treatment of acute lymphoblastic leukemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226022A Division JP5955921B2 (ja) | 2008-11-07 | 2014-11-06 | 急性リンパ芽球性白血病の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508164A JP2012508164A (ja) | 2012-04-05 |
| JP2012508164A5 true JP2012508164A5 (enExample) | 2013-03-21 |
| JP5647132B2 JP5647132B2 (ja) | 2014-12-24 |
Family
ID=41692882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533633A Active JP5647132B2 (ja) | 2008-11-07 | 2009-11-06 | 急性リンパ芽球性白血病の治療 |
| JP2014226022A Active JP5955921B2 (ja) | 2008-11-07 | 2014-11-06 | 急性リンパ芽球性白血病の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226022A Active JP5955921B2 (ja) | 2008-11-07 | 2014-11-06 | 急性リンパ芽球性白血病の治療 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20130323247A1 (enExample) |
| EP (2) | EP2982696B1 (enExample) |
| JP (2) | JP5647132B2 (enExample) |
| KR (1) | KR101695327B1 (enExample) |
| CN (2) | CN102209728A (enExample) |
| AU (4) | AU2009313040B2 (enExample) |
| BR (1) | BRPI0921482B1 (enExample) |
| CA (1) | CA2742249C (enExample) |
| CY (2) | CY1117033T1 (enExample) |
| DK (2) | DK2982696T3 (enExample) |
| ES (2) | ES2558434T3 (enExample) |
| HR (2) | HRP20151168T1 (enExample) |
| HU (2) | HUE028175T2 (enExample) |
| IL (1) | IL212652A (enExample) |
| LT (1) | LT2982696T (enExample) |
| ME (2) | ME02363B (enExample) |
| MX (1) | MX2011002927A (enExample) |
| NZ (1) | NZ591311A (enExample) |
| PL (2) | PL2342227T3 (enExample) |
| PT (2) | PT2342227E (enExample) |
| RS (2) | RS58827B1 (enExample) |
| RU (1) | RU2536940C2 (enExample) |
| SI (2) | SI2982696T1 (enExample) |
| SM (2) | SMT201900278T1 (enExample) |
| WO (1) | WO2010052014A1 (enExample) |
| ZA (1) | ZA201103255B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1976886E (pt) * | 2005-12-16 | 2015-03-09 | Amgen Res Munich Gmbh | Meios e processos para o tratamento de doenças tumorais |
| HUE028175T2 (en) * | 2008-11-07 | 2016-12-28 | Amgen Res Munich Gmbh | Treatment of acute lymphoblastic leukemia |
| US8840888B2 (en) | 2009-10-27 | 2014-09-23 | Micromet Ag | Dosage regimen for administering a CD19XCD3 bispecific antibody |
| HUE048639T2 (hu) * | 2010-10-27 | 2020-08-28 | Amgen Res Munich Gmbh | Eljárás DLBCL kezelésére |
| EP3228315B1 (en) * | 2010-11-10 | 2020-11-25 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
| CA2832360C (en) * | 2011-04-28 | 2022-05-03 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| WO2015121383A1 (en) * | 2014-02-12 | 2015-08-20 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| LT3149480T (lt) | 2014-05-30 | 2019-04-25 | Amgen Research (Munich) Gmbh | B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas |
| BR112017004614A2 (pt) | 2014-09-09 | 2018-02-27 | Janssen Biotech, Inc. | terapias de combinação com anticorpos anti-cd38 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| EP3240540B1 (en) | 2014-12-30 | 2022-08-24 | University of Utah Research Foundation | Hdac1,2 inhibitors and methods of using the same |
| US10563194B2 (en) | 2015-02-24 | 2020-02-18 | BioAlta, LLC | Conditionally active biological proteins |
| DK3298033T4 (da) * | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| CN108136218B (zh) | 2015-05-20 | 2022-12-13 | 詹森生物科技公司 | 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
| DK3298042T3 (da) * | 2015-05-20 | 2025-02-24 | Amgen Res Munich Gmbh | B-celledepletering som en diagnostisk markør |
| NZ777133A (en) | 2015-06-22 | 2025-05-02 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CN105154440B (zh) * | 2015-08-14 | 2016-11-30 | 深圳市瀚海基因生物科技有限公司 | 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| RS61651B1 (sr) | 2015-11-03 | 2021-04-29 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
| RU2651776C2 (ru) * | 2015-12-01 | 2018-04-23 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | Биспецифические антитела против cd3*cd19 |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| CN109476756B (zh) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| AU2018383679B2 (en) | 2017-12-11 | 2025-10-09 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
| KR102083481B1 (ko) | 2018-03-22 | 2020-03-02 | 강원대학교산학협력단 | 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물 |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| WO2020132810A1 (en) * | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| BR112021014255A2 (pt) * | 2019-01-30 | 2022-01-18 | Wistar Inst | Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| WO2020252442A1 (en) * | 2019-06-13 | 2020-12-17 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
| US20230146593A1 (en) | 2020-03-12 | 2023-05-11 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| WO2023062188A1 (en) | 2021-10-15 | 2023-04-20 | Amgen Research (Munich) Gmbh | Subcutaneous administration of cd19-binding t cell engaging antibodies |
| US12319747B2 (en) | 2023-07-03 | 2025-06-03 | Medicovestor, Inc. | Methods of using anti-SP17 immunotherapeutics |
| US12364777B2 (en) | 2023-10-20 | 2025-07-22 | Medicovestor, Inc. | Homodimeric antibodies for use in treating cancers and methods of use |
| WO2025137344A1 (en) | 2023-12-20 | 2025-06-26 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| US12116410B1 (en) | 2023-12-26 | 2024-10-15 | Medicovestor, Inc. | Methods of manufacturing dimeric antibodies |
| US12378314B1 (en) | 2024-02-02 | 2025-08-05 | Medicovestor, Inc. | Proteins that bind folate receptor alpha including fully-human antibodies |
| US12258396B1 (en) | 2024-02-02 | 2025-03-25 | Medicovestor, Inc. | Methods of using immunotherapeutics that bind folate receptor alpha |
| US12240900B1 (en) | 2024-02-02 | 2025-03-04 | Medicovestor, Inc. | Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008875A1 (de) * | 1996-08-28 | 1998-03-05 | Viva Diagnostika Diagnostische Produkte Gmbh | Kombinationspräparationen und ihre verwendung in der immundiagnostik und immuntherapie |
| JP4169478B2 (ja) * | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| BG65066B1 (bg) * | 1998-04-21 | 2007-01-31 | Micromet Gessellschaft Fur Biomedicinische Forschung Mbh | CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US8076459B2 (en) * | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| PT1976886E (pt) * | 2005-12-16 | 2015-03-09 | Amgen Res Munich Gmbh | Meios e processos para o tratamento de doenças tumorais |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| ES2402591T3 (es) * | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| HUE028175T2 (en) * | 2008-11-07 | 2016-12-28 | Amgen Res Munich Gmbh | Treatment of acute lymphoblastic leukemia |
| PL2511264T3 (pl) * | 2009-01-19 | 2015-08-31 | Abbvie Inc | Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
| AU2010204555B2 (en) * | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN102459236B (zh) * | 2009-05-27 | 2014-10-29 | Abbvie公司 | 激酶活性的嘧啶抑制剂 |
| CA2771984A1 (en) * | 2009-09-20 | 2011-03-24 | Abbott Laboratories | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
| US8840888B2 (en) * | 2009-10-27 | 2014-09-23 | Micromet Ag | Dosage regimen for administering a CD19XCD3 bispecific antibody |
-
2009
- 2009-11-06 HU HUE09760483A patent/HUE028175T2/en unknown
- 2009-11-06 HU HUE15185767A patent/HUE043326T2/hu unknown
- 2009-11-06 SI SI200931967T patent/SI2982696T1/sl unknown
- 2009-11-06 DK DK15185767.9T patent/DK2982696T3/da active
- 2009-11-06 PT PT97604839T patent/PT2342227E/pt unknown
- 2009-11-06 KR KR1020117010641A patent/KR101695327B1/ko active Active
- 2009-11-06 CN CN2009801443998A patent/CN102209728A/zh active Pending
- 2009-11-06 SI SI200931306T patent/SI2342227T1/sl unknown
- 2009-11-06 AU AU2009313040A patent/AU2009313040B2/en active Active
- 2009-11-06 PL PL09760483T patent/PL2342227T3/pl unknown
- 2009-11-06 BR BRPI0921482-8A patent/BRPI0921482B1/pt active IP Right Grant
- 2009-11-06 CA CA2742249A patent/CA2742249C/en active Active
- 2009-11-06 EP EP15185767.9A patent/EP2982696B1/en active Active
- 2009-11-06 LT LTEP15185767.9T patent/LT2982696T/lt unknown
- 2009-11-06 ES ES09760483.9T patent/ES2558434T3/es active Active
- 2009-11-06 NZ NZ591311A patent/NZ591311A/xx unknown
- 2009-11-06 ES ES15185767T patent/ES2727585T3/es active Active
- 2009-11-06 RS RS20190593A patent/RS58827B1/sr unknown
- 2009-11-06 RU RU2011122819/10A patent/RU2536940C2/ru active
- 2009-11-06 US US13/127,541 patent/US20130323247A1/en not_active Abandoned
- 2009-11-06 MX MX2011002927A patent/MX2011002927A/es active IP Right Grant
- 2009-11-06 CN CN201710366308.1A patent/CN107184977A/zh active Pending
- 2009-11-06 JP JP2011533633A patent/JP5647132B2/ja active Active
- 2009-11-06 PL PL15185767T patent/PL2982696T3/pl unknown
- 2009-11-06 EP EP09760483.9A patent/EP2342227B1/en active Active
- 2009-11-06 ME MEP-2015-181A patent/ME02363B/me unknown
- 2009-11-06 ME MEP-2019-146A patent/ME03480B/me unknown
- 2009-11-06 HR HRP20151168TT patent/HRP20151168T1/hr unknown
- 2009-11-06 PT PT15185767T patent/PT2982696T/pt unknown
- 2009-11-06 WO PCT/EP2009/007970 patent/WO2010052014A1/en not_active Ceased
- 2009-11-06 SM SM20190278T patent/SMT201900278T1/it unknown
- 2009-11-06 RS RS20150797A patent/RS54456B1/sr unknown
- 2009-11-06 DK DK09760483.9T patent/DK2342227T3/en active
-
2011
- 2011-05-03 IL IL212652A patent/IL212652A/en active IP Right Grant
- 2011-05-05 ZA ZA2011/03255A patent/ZA201103255B/en unknown
-
2014
- 2014-11-06 JP JP2014226022A patent/JP5955921B2/ja active Active
-
2015
- 2015-10-06 AU AU2015238784A patent/AU2015238784A1/en not_active Abandoned
- 2015-12-09 CY CY20151101123T patent/CY1117033T1/el unknown
- 2015-12-30 SM SM201500328T patent/SMT201500328B/it unknown
-
2017
- 2017-08-25 AU AU2017219083A patent/AU2017219083B2/en active Active
-
2018
- 2018-11-06 AU AU2018260815A patent/AU2018260815B2/en active Active
- 2018-12-13 US US16/218,797 patent/US11597766B2/en active Active
-
2019
- 2019-05-16 HR HRP20190912TT patent/HRP20190912T1/hr unknown
- 2019-05-17 CY CY20191100527T patent/CY1122366T1/el unknown
-
2023
- 2023-02-03 US US18/164,304 patent/US20240109964A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508164A5 (enExample) | ||
| JP2012508163A5 (enExample) | ||
| HRP20151168T1 (hr) | Lijeäśenje akutne limfoblastiäśne leukemije | |
| HRP20191715T1 (hr) | Liječenje dječje akutne limfoblastične leukemije sa bispecifičnim protutijelima protiv cd3xcd19 | |
| Zhou et al. | 1, 25 (OH) 2D3 induces regulatory T cell differentiation by influencing the VDR/PLC-γ1/TGF-β1/pathway | |
| Lee et al. | Aging enhances classical activation but mitigates alternative activation in the central nervous system | |
| Crane et al. | CXCR4 receptor expression on human retinal pigment epithelial cells from the blood-retina barrier leads to chemokine secretion and migration in response to stromal cell-derived factor 1α | |
| Helming et al. | The molecular basis of macrophage fusion | |
| Jin et al. | TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+ CD161+ T cells to exacerbate gut inflammation | |
| May et al. | α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy | |
| Peligero-Cruz et al. | IL18 signaling promotes homing of mature Tregs into the thymus | |
| US20200352999A1 (en) | Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors | |
| JP2018168183A (ja) | Ｔ制御性細胞の増殖または枯渇方法 | |
| BR112016024072B1 (pt) | método in vitro de estimular uma população de células | |
| Kondo et al. | Mouse gingival single-cell transcriptomic atlas identified a novel fibroblast subpopulation activated to guide oral barrier immunity in periodontitis | |
| CA2877286A1 (en) | Compositions and methods for diminishing an immune response | |
| Bjorgen et al. | NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics? | |
| Zhang et al. | Expression of high mobility group box 1 in inflamed dental pulp and its chemotactic effect on dental pulp cells | |
| Imaeda et al. | Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis | |
| Koutsoumparis et al. | Erythropoietin (rhEPOa) promotes endothelial transdifferentiation of stem cells of the apical papilla (SCAP) | |
| JP2024167242A (ja) | 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療 | |
| CN111593022A (zh) | vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用 | |
| Pajer et al. | Cytokine signaling by grafted neuroectodermal stem cells rescues motoneurons destined to die | |
| Ajouaou et al. | The oxygen sensor prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells | |
| Kim et al. | Bortezomib inhibits the survival and proliferation of bone marrow stromal cells |